Haselmeier Announces the Market Launch of JuniorSTAR® by Sanofi

Zurich, Switzerland, (PresseBox) - The new and reusable half-unit insulin pen JuniorSTAR® is now available in Germany. It is suitable for all insulin types of Sanofi. It provides individual dosage, which can be corrected easily. Furthermore, it has a large display to ensure the correct dosage and is a lightweight companion during the day, especially for young people with diabetes.

"The launch of JuniorSTAR® marks another milestone of a long-term partnership with Sanofi. After the single unit pen TactiPen®, the portfolio is now completed by the half-unit pen JuniorSTAR®. The JuniorSTAR® delivers 1 to 30 units in steps of 0.5. Thanks to the close cooperation of both teams we were able to develop an excellent pen which meets the current very high quality requirements." explains Sandra de Haan, Director Project Management at Haselmeier and responsible project manager for the JuniorSTAR® project.

"The JuniorSTAR® expands our individual portfolio for people suffering from diabetes. This pen offers, especially young people with type 1 diabetes, a flexible and easy handling to lighten their lives with diabetes. The excellent and close cooperation with Haselmeier was an important part for the successful development of the JuniorSTAR® pen." explains Hamit Oualali, Global Device Manager for reusable pens at Sanofi.

This pen comes in red, blue and silver for more flexibility and easy differentiation of various insulin types.

The Chicago Athenaeum, Museum of Architecture and Design already honoured the JuniorSTAR® pen for its new and fully developed technology with the Good Design Award.

About Sanofi

Sanofi-Aventis Deutschland GmbH is a company of the Sanofi Group, a global healthcare leader, which discovers, develops and distributes therapeutic solutions to meet the patients' needs. Sanofi has its core strengths in the field of healthcare with seven growth platforms: diabetes solutions, vaccines, innovative medication, over-the-counter health care products, emerging markets, animal health and Genzyme.

Haselmeier GmbH

Founded in Stuttgart in 1920, Haselmeier is now one of the leading designers and manufacturers of injection systems. The devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. Located in five locations across three continents, we develop and produce innovative technologies for administering medication to improve the health and everyday life of patients.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.